Simin Vakily Asl, MD
Family Medicine · Virginia Beach, VANPI 1174785497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,410 and has fallen 94.5% since, to $132 in 2024. Among family medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$2K
- Novo Nordisk$985
- Bayer$384
- Lilly USA, LLC$372
- Boehringer Ingelheim$362
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,847100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 64 | $1,785 |
| AstraZeneca | 51 | $1,700 |
| Novo Nordisk | 43 | $985 |
| Bayer | 9 | $384 |
| Lilly USA, LLC | 24 | $372 |
| Boehringer Ingelheim | 13 | $362 |
| Pfizer | 16 | $361 |
| Johnson & Johnson | 15 | $261 |
| Merck | 13 | $261 |
| AbbVie | 14 | $225 |
| Dynavax Technologies Corporation | 2 | $149 |
| Amarin Pharma, Inc. | 3 | $146 |
| Sanofi-aventis U.S. LLC | 8 | $129 |
| Astellas Pharma US Inc | 1 | $125 |
| UCB, Inc. | 3 | $112 |
| Bristol Myers Squibb | 6 | $112 |
| Novartis | 5 | $80 |
| Mallinckrodt Hospital Products Inc. | 3 | $53 |
| Aurinia Pharma U.S., Inc. | 2 | $36 |
| Radius Health, Inc. | 2 | $36 |
| Abbott | 1 | $30 |
| Medtronic | 1 | $27 |
| Sobi, Inc | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,865 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 17 | $27,279 |
| TradjentaLinagliptin | 24 | $18,307 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $5,490 |
| Atorvastatin Calcium | 338 | $2,917 |
| Losartan Potassium | 244 | $2,271 |
| Simvastatin | 186 | $1,995 |
| Ezetimibe | 63 | $1,630 |
| FenofibrateFenofibrate Nanocrystallized | 42 | $1,603 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,600 |
| Amlodipine Besylate | 246 | $1,347 |
| Levothyroxine Sodium | 123 | $1,251 |
| Omeprazole | 106 | $1,082 |
| Metformin Hcl | 116 | $886 |
| Metoprolol Succinate | 52 | $875 |
| Rosuvastatin Calcium | 60 | $828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $261 | $27,27917 claims |
| Boehringer IngelheimTradjenta | $362 | $18,30724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Virginia Beach
- Jim-David GaglioneVirginia Beach$24K
- Michael CharlesVirginia Beach$18K
- Glenn McDermottVirginia Beach$18K
- Nasser HambazVirginia Beach$14K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.